Altimmune, Inc. (ALT) shares surged 6.69% in after-hours trading on Tuesday, following positive topline results from Merck's Phase 3 MK-3475A-D77 trial evaluating the subcutaneous administration of pembrolizumab (Keytruda) together with Altimmune's berahyaluronidase alfa (ALT-B4) in combination with chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC).
The trial met its dual primary pharmacokinetic endpoints, demonstrating non-inferior exposure of the subcutaneous pembrolizumab formulation compared to intravenous Keytruda when administered with chemotherapy. Secondary endpoints of efficacy and safety were generally consistent between the two treatment arms.
These positive results suggest that the subcutaneous pembrolizumab formulation, if approved, could improve the treatment experience for patients by reducing administration time and increasing access compared to intravenous infusion. Merck plans to discuss the data with regulatory authorities worldwide as soon as possible.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。